Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2011.

In the third quarter of 2011, we:

  • Achieved a record $143 million in net product sales, representing 21 percent growth over the third quarter of 2010;
  • Recorded $65 million in net sales of Cinryze for the third quarter and $184 million for the 9 month period,  representing Cinryze growth of 33 percent and 48 percent respectively, over the same periods in 2010;
  • Realized non-GAAP adjusted net income of $48 million; GAAP net income reached $28 million;
  • Generated net cash from operations of $53 million;
  • Initiated a Phase 2 study to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with rHuPH20;
  • Commenced the launch of Cinryze in Europe;
  • Attained centralized European Pediatric Use Marketing Authorization (PUMA) for Buccolam for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents from age 3 months to less than 18 years of age;
  • Entered into a licensing agreement with Intellect Neurosciences, Inc. (OTCBB: ILNS) to acquire the worldwide rights to the clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia;
  • Repurchased an additional 5.5 million shares at a cost of approximately $98.9 million that substantially completed the $150 million securities repurchase program, and announced an additional $200 million buyback program;
  • Maintained a working capital of $532 million as of September 30, 2011, including cash, cash equivalents and short-term investments of $460 million; and
  • Entered into a $200 million, 3-year, senior secured, revolving credit facility.

  • "In all aspects of
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
    2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
    3. ViroPharma Announces Additional Securities Repurchase Program
    4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
    6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
    7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
    8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
    9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
    10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
    11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... July 10, 2014 Decision Resources Group finds ... the U.S. Food and Drug Administration,s (FDA) approval of ... Velphoro, which was approved by the FDA in November ... disease (CKD) patients on dialysis. Other key ... (US) Q2 2014 : ...
    (Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
    (Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
    Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
    ... The End of Polio Concert, funded by the ... 2011, in Perth Australia, has resulted in an unprecedented ... The highly publicized and critically acclaimed concert, which ... Polio Eradication Initiative, has resulted in contributions of $50 ...
    ... Conn., Nov. 7, 2011 Planet Biopharmaceuticals, Inc. and ... specialty pharmaceutical company focused on providing products for allergy ... an asset sale of ALLERGY CONTROL PRODUCTS, INC., a ... Jersey limited liability company. Theron E. Odlaug, ...
    Cached Medicine Technology:Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 2Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 3Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 4
    (Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
    (Date:7/13/2014)... July 13, 2014 The federal court ... ) filed against Johnson & Johnson’s Ethicon, Inc. ... which is expected to get underway next month. According ... U.S. District Court, Southern District of West Virginia on ... on August 7, 2014 at 3:00 p.m. July selection ...
    (Date:7/13/2014)... Max International has recently ... be the featured guest at its Charity Exhibition and ... Attendees will learn about Max’s health products and ... basketball games and perform in a 3 point shoot-out. ... and energy-boosting supplements , has recently announced former NBA ...
    (Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace ... Recently, the company has announced its new selection of ... all these outfits are available at discounted prices (from ... supplier is now offering similar discounts for many other ... many other designs for sale, including flower girl dresses, ...
    (Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
    Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
    ... -- Most children born with HIV infection now survive ... death that awaited HIV-infected babies years ago, researchers report. ... AIDS-causing virus, to better understand the effects of treatment ... these kids, at this point, don,t have virus detectable ...
    ... Associations for Dental Research (IADR/AADR) have published two studies ... income individuals. These articles, titled "Income-related Inequalities in Dental ... and "Income Inequality and Tooth Loss in the United ... in the Journal of Dental Research, the official publication ...
    ... By Dennis Thompson HealthDay Reporter , ... and the American Heart Association have put forth an ... attack, stroke and coronary heart disease. The goals ... and illness, however. They place even greater emphasis on ...
    ... Columbia Business School is proud to announce that Frank ... Finance and Economics and the Healthcare and Pharmaceutical Management ... by the Emerald Literati Network. The award recognizes an ... book series published by Emerald Group Publishing, a leading ...
    ... , FRIDAY, April 22 (HealthDay News) -- Lynne Braun spends a ... by their hearts and their health. Braun, who works as ... teaches at the university,s College of Nursing, helps counsel people who ... who,ve had a heart attack or stroke and hope to ...
    ... Healthcare today teleconferenced one of the world,s first live ... to conference attendees in Sao Paolo, Brazil. The meeting, ... of the globe,s largest vascular surgery events and includes ... an endograft device called a repositionable endoprosthesis. ...
    Cached Medicine News:Health News:HIV Kids Growing Up Well, Study Finds 2Health News:IADR/AADR Journal of Dental Research releases studies on oral health inequalities in older people 2Health News:To Get Americans Healthier, U.S. Targets the Heart 2Health News:To Get Americans Healthier, U.S. Targets the Heart 3Health News:To Get Americans Healthier, U.S. Targets the Heart 4Health News:Columbia business school’s Frank Lichtenberg awarded by the Emerald Literati Network 2Health News:Nurse Practitioner Counsels Lifestyle Changes as Key to Heart Health 2Health News:Nurse Practitioner Counsels Lifestyle Changes as Key to Heart Health 3Health News:Scott & White Healthcare broadcasts live surgery to São Paolo, Brazil 2
    ... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
    St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
    The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
    ... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
    Medicine Products: